Day: November 3, 2023

Innofactor Plc Announcement 3.11.2023          Innofactor Plc: Share Repurchase 3.11.2023       In the Helsinki Stock Exchange         Trade date 3.11.2023  Bourse trade Buy  Share IFA1V  Amount 10,000 SharesAverage price/ share 1.0900 EURTotal cost 10,900.00 EUR          Innofactor Plc now holds a total of 401 889 sharesincluding the shares repurchased on 3.11.2023            On behalf of Innofactor Plc         Nordea Bank Oyj         Janne Sarvikivi Sami Huttunen       Additional information:    Sami Ensio, CEO    Innofactor Plc    Tel. +358 50 584 2029    sami.ensio@innofactor.com         www.innofactor.com       AttachmentInnofactor_3.11_trades

Oma Savings Bank Plc Stock Exchange Release 3.11.2023          Oma Savings Bank Plc: Acquisition of own shares 3.11.2023     In the NASDAQ OMX Helsinki         Trade date 3.11.2023  Bourse trade Buy  Share OMASP  Amount 6,000 SharesAverage price/ share 20.5347 EURTotal cost 123,208.20 EUR          Company now holds a total of 183 488 shares  including the shares repurchased on 3.11.2023            On behalf of Oma Savings Bank Plc       Nordea Bank Finland Plc         Janne Sarvikivi Sami Huttunen            For further information, please contact:  Sarianna Liiri    CFO    Tel. +358 40 835 6712    sarianna.liiri@omasp.fi         Minna Sillanpää    CCO    Tel. +358 50 66592    minna.sillanpaa@omasp.fi         www.omasp.fi    ...

First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic response previously observed in preclinical studies Data represent the first successful administration of intratumoral UNO therapy Additional Phase 1 data for UNO expected in 2024 GARDEN CITY, N.Y. and HAMILTON, Bermuda, Nov. 03, 2023 (GLOBE NEWSWIRE) — Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced encouraging first-in-human and first-in-class clinical data demonstrating a promising safety profile and clear evidence of immune system activation via biomarker response. The single agent treatment in...

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking place November 1-5, 2023, both virtually and in-person in San Diego, CA. “We look forward to sharing data that demonstrate the potential for CBO421 to potently inhibit tumor growth as both a monotherapy and in combination with PD-1 therapies,” said Jeffrey Stein, Ph.D. president and chief executive officer of Cidara. “CD73 plays a significant role in contributing...

Intratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoint Inhibition (ICI) therapies MARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the presentation of new preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to take place in San Diego, California, from November 1-5, 2023. Phio’s innovative preclinical study data highlights the benefit of intratumoral injection (IT) of an INTASYL compound targeting...

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA® (pembrolizumab)ORR of 56% in patients with low expression of PD-L1 in the tumorMedian overall survival (mOS) of 20.8 months in second line (2L) and beyond patients treated with CUE-101 monotherapy, compared to the historic reported survival of approximately eight months observed in patients treated in 2L in the KEYNOTE-040 trial of pembrolizumab No dose limiting toxicities (DLTs) observed or maximum tolerated dose (MTD) reached to date with CUE-102 at the dose escalation phase CUE-102 demonstrated a 75%-80% DCR at the 4mg/kg and 2mg/kg doses respectively with two patients demonstrating tumor reductions of -30% and -29%BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) —...

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironmentMP0317 monotherapy shows a favorable safety profile up to the highest planned dosesPatient recruitment of the study’s dose-escalation portion is complete, with final study results expected in H1 2024Data support continued clinical evaluation of MP0317, including in combination studiesZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, will present additional positive data from its Phase 1 study of MP0317 in patients with advanced solid tumors at the 2023 Annual Meeting of the Society for Immunotherapy...

Media ReleaseStatistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes Early increase in absolute lymphocyte count is correlated with the positive Overall Survival results in non-small cell lung cancer patients recently reported at ESMO 2023, and is a potential on-treatment biomarker for clinical benefit Similar immune response biomarkers in the blood were seen in the double-blind, randomized AIPAC Phase IIb trial, which combined efti solely with chemotherapy and did not include any anti-PD-1 therapySYDNEY, AUSTRALIA, Nov. 03, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing...